# JILLION THERAPEUTICS INC.: Advancing DEL-derived Small Molecule Inhibitors of Pathological Tau Toward Preclinical Development for Alzheimer’s Disease and Tauopathies

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | JILLION THERAPEUTICS INC. |
| Location | BROOKLYN, NY |
| Project | Advancing DEL-derived Small Molecule Inhibitors of Pathological Tau Toward Preclinical Development for Alzheimer’s Disease and Tauopathies |
| Project number | 2R44AG085856-02 |
| Mechanism | R44 |
| Institute | National Institute on Aging |
| Award | $1,118,025 |
| Awarded | 2026-09-17 |
| Project period | 2024-09-01 to 2028-05-31 |
| UEI | KNVYBLASYW88 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11407564). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.